Parliament’s Health Committee (ENVI) introduces constructive amendments to SPC Manufacturing waiver vote in its official opinion to the Parliament’s Legal Committee (JURI)

27 November 2018

The introduction of comprehensive SPC manufacturing waiver key to unlocking […]

Health at a Glance Report highlights public value of generic, biosimilar and value added medicines

26 November 2018

The European Commission and OECD – Health at a Glance: […]

Driving local excellence, delivering European results

5 November 2018

Medicines for Europe is glad to announce the occasion of […]

Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers

11 October 2018

There is a concrete risk that disproportionate influence on the […]

CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court

20 September 2018

An English Court has determined that the contested supplementary protection […]

SPC manufacturing waiver moves a step closer as influential European Parliament ENVI Committee supports reform

17 September 2018

Medicines for Europe welcomes the European Parliament’s Committee on Environment, […]

Multi-stakeholder workshop on biosimilar medicines a crucial milestone in achieving increased patient access to biological therapies

14 September 2018

European Organisation for Specialised Nurses (ESNO) launches switch management guide between similar biological medicines – a guide for nurses

26 June 2018

Medicines for Europe members publish disclosure of Transfers of Value to the healthcare community

22 June 2018

Medicines for Europe is committed to bringing accessible, high quality […]

Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest

14 June 2018

The joint 24th Medicines for Europe and 21st IGBA Annual […]